三阴性乳腺癌分子分型与个体化靶向治疗现状
发布时间：2018-12-20 07:07
【摘要】：目的三阴性乳腺癌(triple-negative breast caner,TNBC)异质性大,恶性程度高,预后差,对内分泌治疗及抗HER2治疗均不敏感。本研究总结TNBC的分子分型及靶向治疗的临床研究进展,以明确TNBC靶向治疗的研究现状和前景。方法应用PubMed及CNKI数据库检索系统,以"TNBC、分子分型、和靶向治疗"等为关键词,检索2011-04-2016-04的相关文献。纳入标准:TNBC的分型与靶向治疗。根据纳入标准,最后纳入分析66篇文献。结果根据基因表达谱,TNBC可分为多种分子亚型,主要为"基底细胞样亚型、间充质/间充质干细胞亚型、免疫调节亚型、管腔雄激素受体亚型"。TNBC主要的靶向治疗方式分为5大类:针对DNA修复缺陷的靶向药物、酪氨酸激酶抑制相关的靶向药、PI3K-AKT-mTOR通路抑制剂、免疫检查点抑制剂和雄激素受体抑制剂。其中PARP抑制剂、铂类、PD-L1抑制剂、AKT抑制剂的研究均已进入Ⅲ期临床试验;酪氨酸酶抑制相关靶向药物及PI3K/AKT/mTOR通路抑制剂单药使用的价值有限,可能更适宜多药联合或与传统化疗药物联合应用;雄激素受体抑制剂的治疗价值尚需进一步临床试验的验证。结论 TNBC有多种分子亚型,多种靶向治疗药物处于临床研究阶段,其中PARP抑制剂、铂类、PD-L1抑制剂最具有研究前景。
[Abstract]:Objective: triple negative breast cancer (triple-negative breast caner,TNBC) has high heterogeneity, high malignancy and poor prognosis. It is insensitive to endocrine therapy and anti HER2 therapy. In this study, the molecular classification of TNBC and the clinical research progress of targeted therapy were summarized, in order to clarify the current situation and prospects of TNBC targeted therapy. Methods PubMed and CNKI database retrieval system were used to search the literature of 2011-04-2016-04 with the key words of "TNBC, molecular typing, targeting therapy" and so on. Inclusion criteria: TNBC typing and targeted therapy. According to the inclusion criteria, 66 articles were analyzed. Results according to the gene expression profile, TNBC could be classified into several molecular subtypes, including basal cell-like subtype, mesenchymal stem cell subtype and immunomodulatory subtype. Subtypes of androgen receptor in lumen ". The main targeting therapy for TNBC is divided into five categories: targeted drugs for DNA repair defects, tyrosine kinase inhibition related target drugs, PI3K-AKT-mTOR pathway inhibitors, Immune checkpoint inhibitors and androgen receptor inhibitors. The studies of PARP inhibitors, platinum inhibitors, PD-L1 inhibitors and AKT inhibitors have all entered stage 鈪，
本文编号：2387625
[Abstract]:Objective: triple negative breast cancer (triple-negative breast caner,TNBC) has high heterogeneity, high malignancy and poor prognosis. It is insensitive to endocrine therapy and anti HER2 therapy. In this study, the molecular classification of TNBC and the clinical research progress of targeted therapy were summarized, in order to clarify the current situation and prospects of TNBC targeted therapy. Methods PubMed and CNKI database retrieval system were used to search the literature of 2011-04-2016-04 with the key words of "TNBC, molecular typing, targeting therapy" and so on. Inclusion criteria: TNBC typing and targeted therapy. According to the inclusion criteria, 66 articles were analyzed. Results according to the gene expression profile, TNBC could be classified into several molecular subtypes, including basal cell-like subtype, mesenchymal stem cell subtype and immunomodulatory subtype. Subtypes of androgen receptor in lumen ". The main targeting therapy for TNBC is divided into five categories: targeted drugs for DNA repair defects, tyrosine kinase inhibition related target drugs, PI3K-AKT-mTOR pathway inhibitors, Immune checkpoint inhibitors and androgen receptor inhibitors. The studies of PARP inhibitors, platinum inhibitors, PD-L1 inhibitors and AKT inhibitors have all entered stage 鈪，
本文编号：2387625
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2387625.html
